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Benjamin Schmidb, Kristine Freudea,⁎
aGroup of Stem Cells and Modeling of Neurodegeneration, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of
Copenhagen, Denmark, Grønnegardsvej 7, 1870C Frederiksberg, Denmark
b Bioneer A/S, Kogle Alle 2, 2970 Hørsholm, Denmark
c Institute for Stem Cell Biology and Regenerative Medicine, Bangalore, India
A B S T R A C T
Alzheimer's disease (AD) is the most common form of dementia, affecting millions of people worldwide. Mutations in the genes PSEN1, PSEN2 or APP are known to
cause familial forms of AD with an early age of onset. In this study, specific pathogenic mutations in the APP gene were introduced into an iPSC line from a healthy
individual by the use of CRISPR-Cas9. The study resulted in the generation of two new cell lines, one carrying the V717I APP mutation and one with the KM670/
671NL APP mutation.
Resource table
Unique stem cell lines
identifier
1. BIONi010-C-37
2. BIONi010-C-38
Alternative names of
stem cell lines
1. BIONi010-C London (V717I)
2. BIONi010-C Swedish (KM670/671NL)
Institution Bioneer A/S Hørsholm Denmark and University of Copenhagen
(UCPH) Copenhagen Denmark
Contact information of
distributor
Contact at Bioneer: Benjamin Schmid, bsc@bioneer.dk–
Contact at UCPH: Kristine Freude, kkf@sund.ku.dk
Type of cell lines iPSCs
Origin Human
Cell Source Fibroblasts
Clonality Clonal
Method of reprogram-
ming
Episomal plasmids (Okita et al., 2011)
Multiline rationale Mutated clones
Gene modification YES
Type of modification Induced point mutation
Associated disease Alzheimer's disease (AD)
Gene/locus 1. APP/ Chr21:27264096 2. APP/ Chr21:27269939 and
Chr21:27269938
Method of modification CRISPR-Cas9
Name of transgene or
resistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock
date
February 2018
Cell line
repository/bank
1. (https://hpscreg.eu/cell-line/BIONi010-C-37)
2. (https://hpscreg.eu/cell-line/BIONi010-C-38)
Ethical approval The study was approved by the Ethics Committee of the Capital
Region of Denmark (H-4-2011-157), and written informed
consent was obtained from the participant before enrolment
Resource utility
The exact mechanisms leading to Alzheimer's disease (AD) remain
unknown. In order to increase our understanding of disease develop-
ment and underlying cellular pathological mechanisms, we have es-
tablished two novel iPSC lines containing either a heterozygous V717I
mutation or a heterozygous KM670/671NL mutation in the Amyloid
precursor protein (APP) gene. These mutations are known to result in
familial forms of AD.
Resource details
Mutations in one of the genes PSEN1, PSEN2 and APP are known to
result in familial forms of AD. The two mutations V717I (London) and
KM670/671NL (Swedish) in the APP gene are both used in various
mouse models, such as the common 5xFAD (Oakley et al., 2006). Due to
their strong phenotype, these specific mutations are highly relevant for
establishment of iPSC based disease models that carry a single patho-
genic mutation. The iPSC model is supported by other models and pa-
tient phenotype information, which will facilitate validation of the in
vitro model and provide further knowledge about the mutations and
AD.
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For this study, the V717I mutation or the KM670/671NL mutation
was inserted into the human iPSC line BIONi010-C, which had earlier
been established from a skin biopsy obtained from a healthy male in-
dividual aged 18 (Rasmussen et al., 2014).
To generate a cell line containing the V717I mutation, the point
mutation resulting in an amino acid change from valine (V) to iso-
leucine (I) was knocked into the APP gene by using the CRISPR-Cas9
system (Jinek et al., 2012). The CRISPR system was also used to insert
the KM670/671NL double mutation resulting in an amino acid change
from lysine (K) and methionine (M) to asparagine (N) and leucine (L)
Fig. 1. Characterization of two iPSC lines with either a heterozygous V717I or a heterozygous KM670/671NL mutation in the APP gene.
(A) DNA sequencing for the heterozygous V717I (London), heterozygous KM670/671NL (Swedish) APP mutation and parental non gene edited iPSC line.
(B) ICC for pluripotency markers: OCT4 (green) nuclear labeling, NANOG (green) nuclear labeling, TRA1-60 (red) cytoplasmatic labeling and SSEA3 (green)
cytoplasmatic labeling. Scale bar represents 25 μm.
(C) FACS analysis of pluripotency markers: OCT4+ SOX2 and TRA1-81+SSEA4. SSEA1 served as a negative control for pluripotency. Upper right quadrant in the
FACS plots represents double positive cells, thereby determined as pluripotent.
(D) ICC for differentiation markers representing the three different germ layers: AFP (green) for endoderm, SMA (red) for mesoderm and TUJ1 (red) for ectoderm.
OCT4 labeling served as negative control for successful spontaneous differentiation.
(E) FACS analysis of differentiation markers: CD56+CD34 (mesoderm), SOX17+CD184 (endoderm) and PAX6+SOX1 (ectoderm). Upper right quadrant in the
FACS plots represents double positive cells, thereby determined as differentiated into the respective lineage.
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into the APP gene.
For both mutations, the nucleotide substitution was confirmed by
restriction digest (Supplementary Fig. 1E), followed by DNA sequen-
cing. Sequencing analysis confirmed a successful G > A transition
causing the V717I mutation on protein level, and a successful G > T
and A > C transition causing the KM670/671NL mutation on protein
level (Fig. 1A). The two lines are further referred to as BIONi010-C-
London and BIONi010-C-Swedish, respectively.
Pluripotency of the gene-edited lines was confirmed by im-
munocytochemistry (ICC) (Fig. 1B) and quantified by flow analysis
(Fig. 1C) showing expression of the pluripotency markers OCT4,
NANOG, SSEA3, SSEA4, TRA-1-81, TRA-1-60 and SOX2. The differ-
entiation potential of the iPSCs was tested via directed- and sponta-
neous differentiation into endo-, meso- and ectodermal cell types. The
test showed that the cells were capable of differentiation into all three
germlayers (Fig. 1D and E) and that iPSCs do not express any differ-
entiation markers (Supplementary Fig. 1D). A karyotype analysis was
carried out to confirm chromosomal integrity (Supplementary Fig. 1A),
and a STR analysis was performed to confirm cell line identity (Avail-
able with author). The morphology of the cells was investigated by light
microscopy and showed a normal morphology throughout the process
of gene editing (Supplementary Fig. 1B). Finally, cells were tested ne-
gative for mycoplasma (Supplementary fig. 1C).
Materials and methods
Gene editing
Cells were grown on Matrigel coated plates in E8 media and in-
cubated at 37 °C and 5% CO2. Cells were passaged every 4 days using
Accutase in a ratio of 1:3. When reaching 80% confluency, cells were
detached by using Accutase for 5min after which cells were nucleo-
fected. Nucleofection was made by using the Lonza nucleofector, P3
solution and the CA167 pulse setting Table 1.
Gene editing was performed using the CRISPR-Cas9 system in
combination with a specifically designed ssODN (single stranded oligo
deoxynucleotide) as homologous template. The template contained ei-
ther the London mutation or the Swedish mutation in combination with
silent mutations (changing the DNA sequence but not the protein se-
quence) to avoid repeated cutting by the CRISPR-Cas9. The pathogenic
mutation is also a recognition site for a specific restriction enzyme. For
London, Bcl1 recognize the mutation and for Swedish, Tfi1 recognize
the mutation. The 20 nt crRNA was designed using the software http://
crispr.mit.edu/. crRNA, tracrRNA, ssODN, and Cas9 protein were all
ordered from Integrated DNA Technologies (IDT) and the CRISPR
system assembled ex vivo.
Genotyping and restriction enzyme
To screen for positive clones, DNA was extracted using the prepGEM
kit (ZyGEM) followed by amplification of the gene by using PCR with
the AmpliTaq GOLD DNA polymerase (Thermo Fisher) according to the
manufacturer's instructions. Annealing temperature: 600C, elongation
time 30 s, 40 cycles in a T100 thermocycler (BioRad). The primers
SURV APP London FW/RV and SURV APP Swedish (IDT) used for PCR,
were designed to cover the mutation at locus
Chr21:27269939+27,269,938 or the mutation at locus
Chr21:27264096. These give rise to a 512 bp product size for Swedish
and 694 bp for London. (Table 3). The screening was carried out by
making a restriction digest on the PCR product, using Tfi1 for 1 h at
650C (Swedish) or Bcl1 for 1 h at 500C (London) (New England Bio-
labs).
Sequencing
The PCR product from positive clones were sequenced by Sanger
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
BIONi010-C-37 BIONi010-C London Male 18 African GA AD
BIONi010-C-38 BIONi010-C Swedish Male 18 African GT/AC AD
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Supplementary Fig. 1 panel B
Phenotype Qualitative analysis by
immunocytochemistry
Both cell lines are positive for OCT4, NANOG, SSEA3 and TRA-1-60 Fig. 1 panel B
Quantitative analysis by flow
cytometry
BIONi010-C APP London positive for: 89,8% double positive for
OCT4 and SOX2.
86,9% are double positive for TRA-1-81 and SSEA4.
1.02% are positive for SSEA1(control).
BIONi010-C APP Swedish positive for: 94.1% double positive for OCT4
and SOX2.
84.2% double positive for SSEA4 and TRA1–81.
0.79% SSEA1(control).
Fig. 1 panel C
Genotype Karyotype (G-banding), Resolution
300–400
Both 46XY Supplementary Fig. 1 panel A
Identity STR analysis DNA profiling performed Available with author
16 sites tested, all match
Mutation analysis Sequencing Successful integration of heterozygous mutation G > A causing V717I
and heterozygous integration of the double mutation GA > TC causing
KM670/671NL.
Fig. 1 panel A
Microbiology and
virology
Mycoplasma Mycoplasma testing by PCR Mycoplasma Test Kit Supplementary Fig. 1C
Differentiation potential Directed differentiation Specific differentiation markers for all 3 germ layers present in both lines
after differentiation
Fig. 1 panel E (control with iPSCs
Supplementary Fig. 1 panel D)
Spontaneous differentiation Positive for: AFP, SMA and TUJ1. Negative for OCT4 Fig. 1 panel D
H.R. Frederiksen et al. Stem Cell Research 34 (2019) 101368
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sequencing using the primers SURV APP London seq and SURV APP
Swedish seq (Table 3).
Karyotyping and quality control
Quality control was performed after the lines had been banked and
the quality controls are listed in Table 2. The general morphology of the
cells was investigated daily by light microscopy. Karyotyping was made
at passage 41 for cells carrying the APP London mutation (20 passages
after nucleofection), and at passage 39 for cells carrying the APP
Swedish mutation (18 passages after nucleofection). When cells were
70–85% confluent, karyotyping was initiated by treating cells with
Colcemid (Gibco) for 1.5 h after which cells were detached with Ac-
cutase for 5min. Next, cells were incubated with 0.075M KCl for
30min at 370C, and afterwards fixed by using a mixture consisting of
25% acidic acid and 75% methanol. Fixed cells were cooled overnight
at -20 °C and then shipped for GTG-band karyotyping at Anand Diag-
nostic Laboratory, Bangalore where 20 metaphase spreads were
counted. STR analysis was performed by extracting DNA with the
DNeasy Blood and Tissue Kit (Qiagen) and subsequently analysing the
DNA using the AmpFLSTR Identifier PCR Amplification kit (Applied
Biosystem) according to manufacturer's instructions. Microbiological
contamination was tested by growing 500 μl of the supernatant in LB
medium for 2 days at 370C. Cells were tested for mycoplasma using the
PCR mycoplasma test kit (PromoKine) according to manufacturer's in-
structions.
Immunocytochemistry
Expression of pluripotency markers, were investigated using a Leica
DMRB-fluorescence microscope (Leica Microsystems Wetzlar,
Germany). Cells were fixed in 4% PFA for 20min at RT and labeled
according to standard ICC procedures by permeabilising fixed cells with
0,2% Triton X-100 in PBS for 20min at RT followed by 30min of
blocking with 3% BSA. All antibodies were diluted in 3% BSA in ac-
cordance with Table 3. The primary antibodies (OCT4, NANOG, SSEA4,
SSEA3, Tra-1-60 and Tra-1-81) were incubated at 4 °C overnight and
were visualised with the secondary antibodies Alexa488 or Alexa647
(Life Technologies) diluted 1:200 in BSA. Secondary antibodies were
incubated for one hour at RT and in darkness. In all samples, Hoechst
bisbenzimide 33,258 was used to stain the nuclei.
Trilineage differentiation
IPSCs were cultured for differentiation into mesoderm, ectoderm or
endoderm following two different approaches. One method is by
making directed differentiation for 5 days. For mesoderm differentia-
tion, cells were cultured for 3 days in mesodermal induction medium
(MIM) consisting of StemDiff™ APEL™ medium (STEMCELL
Technologies) with 0,1% Pen/Strep (Lonza), 25 ng/ml Activin A (Cell
Guidance Systems), 30 ng/ml BMP4 (Peprotech), 50 ng/ml VEGF
(Peprotech) and 1,5 μM CHIR99021 (Selleckchem). For the last two
days cells were cultured in vascular specification medium (VSM) con-
sisting of StemDiff™ APEL™ medium with 0.1% Pen/strep, 50 ng/ml
VEGF and 10 μM SB431542 (Selleckchem). For endoderm differentia-
tion, cells were cultured for 5 days in MCDB131–1 medium (Sigma)
containing glucose (Sigma), GlutaMAX (Gibco), Pen/Strep, NaHCO3
(Gibco), BSA (Sigma) and Activin A. For the first 24 h 3 μM CHIR99021
was added to the media. For ectoderm differentiation, cells were cul-
tured in neural induction medium (NIM) consisting of 1:1 DMEM/F12
(Gibco) and Neurobasal medium (Gibco). The NIM contains 1% N2
(Gibco), B27 without Retinoic acid (Gibco), GlutaMAX (Gibco), Pen/
Strep (Lonza) and the inhibitors SB431542 (Selleckchem) and
LDN193189 (Selleckchem). After five days, expression of the markers,
PAX6/SOX1 (ectoderm), CD34/CD54 (mesoderm) and CD184/SOX17
(endoderm) were analysed by Flow cytometry.
The other method, involves growing the iPSC as embryoid bodies.
Embryoid bodies were formed by treating 80% confluent iPSCs with
Accutase for 1min and detaching them using a cell scraper. Afterwards
cells were transferred to low attachment plates where they were left to
grow in E8 media for 7 days with media change every second day. After
7 days, they were plated on Matrigel coated plates, and left to sponta-
neously differentiate for 14 days in fibroblast media (DMEM +10%
FBS+0.1% Pen/Strep). Afterwards, ICC was performed for smooth
muscle-actin (mesoderm), alpha 1-fetoprotein (endoderm) and beta-3-
tubulin (ectoderm) and evaluated using a Leica DMRB-fluorescence
microscope.
Flow cytometry
Cells for flow cytometry were detached with Accutase for 5–10min
and 0.2×105 cells were fixed in a 0.5 ml solution consisting of 1 part
Foxp3 fixation solution and 3 parts permeabilisation solution (R&D
systems) and incubated at RT for 30min. Cells were washed in 1×
permeabilisation buffer (R&D systems) after which antibodies diluted in
100 μl permeabilisation buffer, were added for 45min at RT.
Cells were washed additionally three times and afterwards run at a
calibrated BD Accuri C6 Flow Cytometer. 50.000 cells were analysed
with the BD Accuri C6 Flow Cytometer system at high speed in 150 μl
buffer. The data was analysed by using the FlowJo_V10 software.
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